Chimeric Therapeutics
- Short interest
- 0.00%
- −0.13 pp 30d
- as of 11 May 2026
- Reported shorts
- 1
- Shares on issue
- 51.822M
Chimeric Therapeutics (CHM) Short Interest
Chimeric Therapeutics (ASX:CHM) had 0.00% of shares reported as short positions as of 11 May 2026, representing 1 shares. Chimeric Therapeutics operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Chimeric Therapeutics
Chimeric Therapeutics is an Australian clinical-stage cell therapy company focused on developing and commercializing innovative cell therapies for cancer patients. Their diversified portfolio includes autologous CAR T-cell therapies and allogeneic NK cell therapies, targeting multiple oncology disease areas. The company currently has several clinical trials underway.
Company profile →Chimeric Therapeutics (ASX:CHM) has 0.00% of its shares on issue reported as short positions as of 11 May 2026, or about 1 shares. Over the past 30 days that figure has fallen 0.13 percentage points, and over 90 days it has fallen 0.13 percentage points. Its highest recorded short interest was 0.64% in October 2024. CHM is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads CHM today
- Zanger BreakoutNot a candidate
- CAN SLIMNot a candidate
- Minervini Trend TemplateNot a candidate
- Crowded-Short BreakoutNot a candidate
- Quality compoundersNot a candidate
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
CHM fundamentals
In the year to 30 Jun 2026, Chimeric Therapeutics (ASX:CHM) recorded revenue of A$0 and a net loss after tax of A$18.8M. A year earlier it recorded revenue of A$4.0M and a net loss after tax of A$10.4M. Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest CHM news
All news- Ceasing to be a substantial holder from MFG
asx · 7 Oct 2026
- Notice of initial substantial holder from MFG
asx · 5 Oct 2026
- Final Director's Interest Notice - LR
asx · 4 Oct 2026
Company details
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss CHM
Start a research thread or post the first pulse update